Breaking News

Nexcella Completes 2nd NXC-201 Engineering Batch

Supports expansion of its ongoing NEXICART-1 clinical trial to the U.S.

Nexcella, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, reported the successful completion of its second CAR-T NXC-201 engineering batch at its U.S. manufacturing site. This represents an important step forward in the planned U.S. expansion of the company’s ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. “The completi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters